Li Cheng-Hai, Zhao Jing, Zhang Hong-Yan, Wang Bin
Stem Cell Program of Clinical Research Center, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Zhengzhou 450003, Henan Province, China.
Department of Clinical Laboratory, People's Hospital of Zhengzhou University and Henan Provincial People's Hospital, Zhengzhou 450003, Henan Province, China.
World J Stem Cells. 2023 Apr 26;15(4):105-119. doi: 10.4252/wjsc.v15.i4.105.
Mesenchymal stromal/stem cells (MSCs) are currently applied in regenerative medicine and tissue engineering. Numerous clinical studies have indicated that MSCs from different tissue sources can provide therapeutic benefits for patients. MSCs derived from either human adult or perinatal tissues have their own unique advantages in their medical practices. Usually, clinical studies are conducted by using of cultured MSCs after thawing or short-term cryopreserved-then-thawed MSCs prior to administration for the treatment of a wide range of diseases and medical disorders. Currently, cryogenically banking perinatal MSCs for potential personalized medicine for later use in lifetime has raised growing interest in China as well as in many other countries. Meanwhile, this has led to questions regarding the availability, stability, consistency, multipotency, and therapeutic efficiency of the potential perinatal MSC-derived therapeutic products after long-term cryostorage. This opinion review does not minimize any therapeutic benefit of perinatal MSCs in many diseases after short-term cryopreservation. This article mainly describes what is known about banking perinatal MSCs in China and, importantly, it is to recognize the limitation and uncertainty of the perinatal MSCs stored in cryobanks for stem cell medical treatments in whole life. This article also provides several recommendations for banking of perinatal MSCs for potentially future personalized medicine, albeit it is impossible to anticipate whether the donor will benefit from banked MSCs during her/his lifetime.
间充质基质/干细胞（MSCs）目前应用于再生医学和组织工程。大量临床研究表明，来自不同组织来源的MSCs可为患者提供治疗益处。源自人类成人或围产期组织的MSCs在其医学应用中各有独特优势。通常，临床研究是通过使用解冻后的培养MSCs或短期冷冻保存后再解冻的MSCs进行给药，以治疗多种疾病和医学病症。目前，在中国以及许多其他国家，将围产期MSCs低温保存以备潜在的个性化医疗终生使用，已引起越来越多的关注。与此同时，这也引发了关于长期冷冻保存后潜在的围产期MSCs衍生治疗产品的可用性、稳定性、一致性、多能性和治疗效率的问题。本观点综述并未忽视围产期MSCs在短期冷冻保存后对许多疾病的治疗益处。本文主要描述了中国围产期MSCs低温保存的相关情况，重要的是，要认识到低温保存库中用于终生干细胞医学治疗的围产期MSCs的局限性和不确定性。本文还为围产期MSCs低温保存提出了一些建议，以备未来潜在的个性化医疗之需，尽管无法预测捐赠者在其一生中是否会从低温保存的MSCs中受益。
